Massey researchers uncover pathway that could transform glioblastoma treatment options

Newly published work in Neuro-Oncology spotlights a molecular vulnerability in glioblastoma (GBM), the most aggressive primary brain tumor. The study, led by researchers at Virginia Commonwealth University (VCU) and the VCU Massey Comprehensive Cancer Center together with colleagues from UT MD Anderson Cancer Center, identifies TRNAU1AP as a protein that helps GBM cells survive, expand, and sustain tumor growth.

Glioblastoma remains difficult to treat largely because cancer stem-like cells drive regrowth and therapy resistance. Although median survival has improved to roughly 14 months with modern combinations—including brachytherapy surgery and chemotherapy—long-term control is still rare.

The research team combined analyses of GBM tumor samples with public datasets to map how TRNAU1AP correlates with disease severity. They report that higher TRNAU1AP levels associate with worse patient outcomes, suggesting the protein is not merely a biomarker but an actionable component of tumor biology.

Mechanistically, TRNAU1AP appears to organize into small intracellular clusters via phase-separation–linked behavior. These clusters help sustain the translation of selected selenoproteins, proteins that use selenium-dependent chemistry to protect cells from stress and damage. By maintaining this protective program, GBM cells gain a growth advantage.

A second key player in the pathway is IGF2BP3, an m6A “reader” protein. IGF2BP3 recognizes m6A-modified mRNAs—where “m6A” is an N6-methyladenosine epigenetic-like label added to RNA—and shields them from degradation. In GBM, IGF2BP3 binds TRNAU1AP transcripts bearing m6A marks, stabilizing the mRNA and supporting continued TRNAU1AP protein production.

This sets up a coherent therapeutic logic: interrupt the IGF2BP3–TRNAU1AP axis to reduce TRNAU1AP abundance, destabilize the selenoprotein translation program, and increase tumor cell sensitivity to treatment. The authors propose that targeting the pathway could “open up new pathways” to combat a disease that has resisted many approaches.

Next steps focus on drug development—specifically, creating inhibitors of IGF2BP3 capable of crossing the blood–brain barrier. A small-molecule that disrupts IGF2BP3–RNA interactions could lower transcript stability and suppress glioblastoma growth.

Overall, the study reframes GBM progression around RNA-label recognition and phase-separation-linked protein organization, offering a viral-science-news–worthy target for future translational strategies.